Results 271 to 280 of about 260,886 (316)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2014
e18516 Background: Lung cancer has a poor prognosis, with 15-20% five-years survival rate. However, lung cancer treatment has in the last years taken advantage of newly developed targeted therapies...
Åslaug Helland +9 more
openaire +1 more source
e18516 Background: Lung cancer has a poor prognosis, with 15-20% five-years survival rate. However, lung cancer treatment has in the last years taken advantage of newly developed targeted therapies...
Åslaug Helland +9 more
openaire +1 more source
Durvalumab Promising for NSCLC
Cancer Discovery, 2017Abstract The PD-L1 inhibitor durvalumab increases progression-free survival and objective response rate in patients with inoperable and locally advanced stage III non–small cell lung cancer, according to interim results of a phase III trial. The benefit was great enough that the drug could become the standard of care in the United States
openaire +2 more sources
Sevabertinib (Hyrnuo) for NSCLC
The Medical Letter on Drugs and TherapeuticsSevabertinib (Hyrnuo – Bayer), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of adults with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with human epidermal growth factor 2 (HER2) tyrosine kinase domain activating mutations who had received prior systemic therapy.
openaire +2 more sources
Zongertinib (Hernexeos) for NSCLC
The Medical Letter on Drugs and TherapeuticsZongertinib (Hernexeos – Boehringer Ingelheim), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of adults with unresectable or metastatic nonsquamous non-small cell lung cancer (NSCLC) with human epidermal growth factor 2 (HER2) tyrosine kinase domain activating mutations who had received prior systemic therapy ...
openaire +2 more sources
Sunvozertinib (Zegfrovy) for NSCLC
The Medical Letter on Drugs and TherapeuticsSunvozertinib (Zegfrovy – Dizal), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations who had disease progression on or after platinum-based chemotherapy.
openaire +2 more sources
Genetic Mutations Associated With NSCLC and Molecular Subtypes of NSCLC
Non-small cell lung cancer (NSCLC) represents the greatest prevalent sort of lung cancer. NSCLC constitutes nearly eighty percent of the overall incidence of lung cancer. Squamous cell carcinoma (SCC), adenocarcinoma (ADC), and large-cell carcinoma (LCC) are among the three predominant classifications of NSCLC. NSCLC is primarily triggered by anomaliesPadmavathi Vijayakumar +3 more
openaire +1 more source